PFE Pfizer
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
PFE stock data
()
News
Johnson & Johnson's COVID-19 Vaccine: Detroit Mayor Declines 6,200 Doses, Catholic Bishops Raise 'Moral Concerns'
5 Mar 21
PreMarket Prep Stock Of The Day: Norwegian Cruise Line
5 Mar 21
AstraZeneca's COVID-19 Vaccine Potentially Triggers Response Against Brazil Variant: Reuters
5 Mar 21
Pfizer's Plant For Boosting COVID-19 Vaccine Production Has Been Rebuked For Repeat Quality Offenses: Bloomberg
5 Mar 21
WHO, SII Warn Of Raw Materials Shortage For COVID-19 Shots, Cites US Law As 'Serious' Limit:' Bloomberg
5 Mar 21
Press releases
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
4 Mar 21
U.S. FDA Expands Approval of Pfizer's LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
3 Mar 21
As Additional COVID Variants Surface, Questions Arise to Effectiveness of Vaccines to Combat New Strains
1 Mar 21
European Medicines Agency Accepts Pfizer's Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
26 Feb 21
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
26 Feb 21
Calendar
25 Feb 21
6 Mar 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Pfizer earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.83B | 1.83B | 1.83B | 1.83B | 1.83B | 1.83B |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 839M | (positive/no burn) | (positive/no burn) | (positive/no burn) |
| Cash used (since last report) | n/a | n/a | 1.84B | n/a | n/a | n/a |
| Cash remaining | n/a | n/a | -13.51M | n/a | n/a | n/a |
| Runway (months of cash) | n/a | n/a | -0.0 | n/a | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 Feb 21 | Angela Hwang | Common Stock | Payment of exercise | Dispose F | No | No | 34.64 | 6,268 | 217.12K | 26,171 |
| 27 Feb 21 | Angela Hwang | Common Stock | Payment of exercise | Dispose F | No | No | 33.49 | 1,772 | 59.34K | 32,439 |
| 27 Feb 21 | Angela Hwang | Common Stock | Option exercise | Aquire M | No | No | 22.35 | 9,886 | 220.95K | 34,211 |
| 27 Feb 21 | Angela Hwang | Stock Appreciation Rights Common Stock | Option exercise | Dispose M | No | No | 22.35 | 9,886 | 220.95K | 0 |
| 27 Feb 21 | Frank A Damelio | Common Stock | Payment of exercise | Dispose F | No | No | 34.64 | 96,872 | 3.36M | 483,188 |
| 27 Feb 21 | Frank A Damelio | Common Stock | Payment of exercise | Dispose F | No | No | 33.49 | 27,381 | 916.99K | 580,060 |
| 27 Feb 21 | Frank A Damelio | Common Stock | Option exercise | Aquire M | No | No | 22.35 | 152,785 | 3.41M | 607,441 |
| 27 Feb 21 | Frank A Damelio | Stock Appreciation Rights Common Stock | Option exercise | Dispose M | No | No | 22.35 | 152,785 | 3.41M | 0 |
| 27 Feb 21 | Jennifer B. Damico | Common Stock | Payment of exercise | Dispose F | No | No | 34.64 | 6,268 | 217.12K | 16,248 |
| 27 Feb 21 | Jennifer B. Damico | Common Stock | Payment of exercise | Dispose F | No | No | 33.49 | 1,229 | 41.16K | 22,516 |
Institutional ownership Q4 2020
65.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2560 |
| Opened positions | 276 |
| Closed positions | 165 |
| Increased positions | 1216 |
| Reduced positions | 884 |
13F shares |
Current |
|---|---|
| Total value | 135.5B |
| Total shares | 3.68B |
| Total puts | 56.14M |
| Total calls | 63.75M |
| Total put/call ratio | 0.9 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 447.96M | $16.49B |
| BLK Blackrock | 396.97M | $14.61B |
| STT State Street | 279.58M | $10.29B |
| Capital World Investors | 266.65M | $9.82B |
| Wellington Management | 246.49M | $9.07B |
| Geode Capital Management | 90.45M | $3.32B |
| BAC Bank Of America | 68.49M | $2.52B |
| NTRS Northern Trust | 66.72M | $2.46B |
| BK Bank Of New York Mellon | 64.76M | $2.38B |
| Norges Bank | 60.3M | $2.22B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Celldex Therapeutics • Acura Pharmaceuticals • Immucell • Heron Therapeutics • Brickell BiotechContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
AAH, AbbVie, ABO, Abrilada, absolute, academic, Academy, accompanying, accrual, acetate, actuarial, adjacent, adolescent, ADP, adult, Advair, affirmed, agricultural, Aid, allegedly, Allergan, alongside, Amgen, AML, amortization, amortize, amortized, AMPA, amplified, amplify, amplifying, Amsparity, Ankylosing, anonymity, antagonist, anytime, AOCI, apixaban, Appellate, ARCA, arrive, ARYA, ASR, assign, assigned, assumption, atopic, attained, Aug, Aurobindo, autoinjector, Automatically, automation, avoidance, aware, bacteria, Baltimore, Bankruptcy, barring, behavior, beneficiary, bevacizumab, Biden, billed, binding, binimetinib, BIO, Biogen, BioNTech, BOD, body, Bold, bond, book, booster, Bosulif, Bound, breakthrough, breast, Bresch, brick, brightest, Brook, buy, buying, Cadila, Calcium, CAR, Carapezzi, cardiac, Carlo, castration, causation, CDC, cease, ceased, CERE, certified, cessation, cetuximab, Chapter, characterize, charitable, chemotherapy, Citibank, Citrate, clarifying, clothing, cloud, CMA, collateral, colleague, Colorado, Columbia, commingled, complaint, composite, composition, conjunction, Connecticut, consecutive, conservative, correlate, correlation, corridor, corroborated, Cortexyme, counterbalance, counterclaim, counterparty, coupon, courage, COVAX, Crohn, crystalline, CStone, culmination, cumulative, curtailed, Cyanamid, cycle, cytarabine, daily, damico, deadline, Dec, deconsolidated, decree, deep, defense, delinquency, delisted, denial, derecognition, derecognized, destroyed, device, disallowance, discharge, discriminating, disgorgement, dismissed, dismissing, disputed, diversification, diversified, dividend, Docetaxel, double, doughnut, DRG, EEA, ehf, Eli, EMD, emotional, empowering, enantiomer, encorafenib, endpoint, energized, engineering, England, enjoining, enrichment, enrollment, enzalutamide, EPA, epidemiological, epinephrine, EpiPen, EPS, equate, Erbitux, erode, error, ertugliflozin, ESG, ESOP, estate, estradiol, ethnic, ethnically, EUA, evenly, examined, examining, excellence, exempt, exemption, exhausted, expedient, experiential, expressed, fairly, FASB, feasibility, feasible, Feb, feedback, feel, fiduciary, filer, finite, flat, fleet, Florida, forfeited, forfeiture, FORMSFOR, formula, Fosun, France, franchise, French, froze, fusion, futility, GAAP, GDFV, gender, gene, geopolitical, germline, Glenmark, GmbH, GnRH, Governor, great, groundwater, guarantor, guideline, hair, handling, Haven, healthy, heard, hearing, Heather, Hexal, hierarchy, highest, HIPAA, HIV, hole, Hong, honoring, hyperinflationary, hypothetical, Idec, idiopathic, illiquid, ImClone, immaterial, immunodeficiency, implicit, implied, Imputed, inception, incidence, incremental, indefinite, indefinitely, indemnified, indemnify, indemnifying, indemnity, indirectly, induced, inestimable, Infant, infection, infiltration, inflationary, influenza, ingestion, inhalation, Inhub, Inquiry, installment, institution, interdicting, intermediary, interval, intraperiod, intrinsic, invasive, inventory, investee, invoice, invoiced, Iraqi, IRC, Irrungattukottai, IRS, ISDA, Jan, jennifer, job, joy, JPO, judgment, Justice, justifying, JV, JVs, Kadian, King, Kong, KPMG, krona, lag, lagged, learning, length, lieu, Lilly, listening, loan, LOE, Lorbrena, Louisiana, lump, lung, Lyme, MA, Macau, macroeconomic, MaddenSenior, mainland, maker, malware, managerial, margin, mask, master, maximum, Mayor, mCRC, mCRPC, MDL, meant, melanoma, mental, mentioned, mentoring, merged, merit, methodology, methotrexate, mg, misrepresented, Mississippi, misstatement, Monsanto, Monte, Monthly, Moody, mortality, mortar, motion, movement, mRNA, multidistrict, Myovant, NaN, NASDAQ, NAV, NDMA, nearest, Neratinib, neuropathic, Neutropenia, NHS, nmCRPC, noncontrolling, noncurrent, norethindrone, Northern, notch, notional, Nov, NRDL, NSCLC, NYU, Nyvepria, obligor, observable, observational, observed, OCI, Oct, Ohio, OID, onForm, onsite, Opiate, OPKO, Optical, Orange, orderly, Orgovyx, outlook, overfunded, Overnight, overseen, owing, PAC, palbociclib, pandemic, Panzyga, paper, par, parent, pause, payable, Payal, payor, payout, PBO, PCAOB, PCPP, permanent, perpetual, perspective, petition, Pharmacia, phishing, phosphate, PIPE, plaintiff, poly, polychlorinated, polymerase, polymorphic, pool, powder, precipitate, precision, predecessor, predetermined, predominately, pregabalin, prejudice, preliminarily, preserve, pro, prodrug, propionate, proportion, proportionately, prorated, protease, proton, proud, provable, provisional, PTC, PTE, PTSRU, Pulse, Puma, pump, punitive, purported, purportedly, purpura, quantifying, Quillivant, quoted, RA, race, Racketeer, radio, Ranbaxy, RAR, Raritan, rata, reader, ready, reallocated, reallocating, recasting, reclassification, reconciling, recoup, recouped, recover, recoverability, recoverable, recovered, recurring, Reddy, redeem, redeemable, redeemed, redemption, reevaluate, refill, refund, refunded, reliant, relugolix, remeasured, remeasurement, remittance, remitted, remote, remotely, renegotiation, rent, rental, reoccur, repay, reserve, reserved, Residual, resiliency, restarted, restitution, RET, retiree, retirement, retrospective, retrospectively, ribose, Rican, rituximab, River, rivipansel, Roche, ROU, royalty, RSC, Russian, Sahni, salmeterol, Sandoz, Sanofi, Sawai, scale, Scheme, Scotland, Scottish, SDNY, SecretaryChief, sentence, Sept, Serono, Servier, Shanghai, shelf, shipment, Shire, shorter, shown, Sildenafil, simpler, simulation, SIP, skill, SOFR, Solutia, sought, Southern, sovereign, Spain, span, SPC, speak, spinal, spot, stable, statewide, statute, statutory, stay, stayed, stemming, stream, strict, sublease, subpoena, subscription, substantive, sued, sugemalimab, Sugen, sum, summarized, superior, superseded, Supreme, survey, suspend, suspended, Sweden, Swedish, syncytial, tablet, Tadalafil, Taiwan, talazoparib, talent, talented, Talzenna, taxable, Taxotere, temperature, temporary, therefrom, thereunder, threshold, thrive, thrombocytopenic, ticker, title, tofacitinib, tolerability, tolerance, Topic, traditional, transmission, travel, Treadway, treble, troubled, TSRU, turnover, TV, twelve, UC, UK, unbudgeted, unchanged, underfunded, underrepresented, underserved, undertaken, underwritten, undiscounted, unduly, unemployment, unforeseen, unissued, unjust, unlawful, unlisted, unobservable, unpaid, unpatented, unprecedented, unqualified, unrealized, unrecognized, unrelated, unremitted, unsecured, unsettled, unused, unvested, upheld, upward, USP, Uterine, Valneva, variation, veto, vi, Virginia, virtual, virtually, visit, vitro, voluntarily, volunteering, Vyndamax, Vyndaqel, wake, war, warrant, weighted, West, whichever, wholly, William, Wixela, WMS, write, XR, Zantac
Removed:
absence, accretion, accumulator, acting, addressed, adulteration, advertised, advice, affiliate, ambiguity, Andover, Appendix, Apple, attached, attempt, authentic, backlog, balanced, bear, cangialosi, cap, cautionary, ceiling, CETA, chemically, clarity, combining, conjugate, consolidating, constantly, Conversely, coordinating, cornwell, counteract, counterfeiting, coupled, crime, Decentralized, deliberately, detected, dictate, disciplined, disguising, distinguish, diversion, don, downturn, draft, easier, easily, economical, electorate, enhancement, evade, eventually, evidentiary, exacerbated, expediting, faced, facilitated, facing, favoring, Federation, firmly, foreseen, gaining, good, harmonizing, heavy, heighten, hyperlinked, ian, Iceland, identity, imported, impractical, inactive, inconsistent, Indian, inspection, intensity, interchangeability, intermediate, interpret, introducing, invalidate, involvement, iran, ITRSHRA, lacking, leading, leveraging, Liechtenstein, lifespan, Likewise, linkage, locate, longstanding, loretta, makeup, matched, matrix, McPherson, mind, MINE, minimal, mislabeled, mounting, multinational, Mutual, Norway, notable, nurse, paradigm, passage, patentability, pave, pendency, pertinent, postal, posting, preclude, premium, presidential, priority, prohibit, prosecute, provincial, punishable, put, reaction, reauthorized, recall, recombinant, referendum, referring, released, repeal, resist, Revatio, revoke, safeguard, serialization, shifting, ship, show, simplifying, skip, solvency, sound, source, steeper, step, streamlining, striving, substandard, sufficiency, sui, supplying, supporting, switch, syria, tendency, textual, theft, therapeutically, therewith, tier, top, trace, training, Translational, transport, Tree, Unaudited, unavailable, unclear, understood, undue, unveiled, upgraded, user, VAI, vital, voluntary, voted, Watch, wider, Xyntha
Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
Current reports
8-K
Pfizer Reports Fourth-quarter and Full-year 2020 Results
2 Feb 21
8-K
Regulation FD Disclosure
12 Jan 21
8-K
Amendments to Articles of Incorporation or Bylaws
14 Dec 20
8-K
Unaudited Pro Forma Condensed Consolidated Financial Statements
19 Nov 20
8-K
Other Events
18 Nov 20
8-K
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
16 Nov 20
8-K
Unregistered Sales of Equity Securities
13 Nov 20
8-K
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
5 Nov 20
8-K
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
30 Oct 20
8-K
Pfizer Reports Third-quarter 2020 Results
27 Oct 20
Registration and prospectus
S-3ASR
Automatic shelf registration
26 Feb 21
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
1 Jun 20
424B5
Prospectus supplement for primary offering
20 May 20
FWP
Free writing prospectus
18 May 20
424B3
Prospectus supplement
18 May 20
425
Business combination disclosure
29 Apr 20
424B5
Prospectus supplement for primary offering
26 Mar 20
425
Business combination disclosure
26 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
PX14A6G
Letter to shareholders
6 Apr 20
PX14A6G
Letter to shareholders
3 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Mar 20
DEF 14A
Definitive proxy
13 Mar 20
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
Other
CT ORDER
Confidential treatment order
14 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
30 May 17
CERTNYS
Certification of approval for NYSE listing
6 Mar 17
NO ACT
No action letter
9 Feb 17
NO ACT
No action letter
30 Jan 17
NO ACT
No action letter
25 Jan 17
NO ACT
No action letter
9 Jan 17
NO ACT
No action letter
26 Dec 16
SD
Conflict minerals disclosure
30 May 16
Ownership
4
PFIZER / Mikael Dolsten ownership change
2 Mar 21
4/A
PFIZER / Mikael Dolsten ownership change
2 Mar 21
4
PFIZER / DOUGLAS M LANKLER ownership change
2 Mar 21
4
PFIZER / JOHN D YOUNG ownership change
2 Mar 21
4
PFIZER / SALLY SUSMAN ownership change
2 Mar 21
4
PFIZER / RADY A JOHNSON ownership change
2 Mar 21
4
PFIZER / ALEXANDER R MACKENZIE ownership change
2 Mar 21
4
PFIZER / Angela Hwang ownership change
2 Mar 21
4
PFIZER / FRANK A DAMELIO ownership change
2 Mar 21
4
PFIZER / JENNIFER B. DAMICO ownership change
2 Mar 21
Patents
APP
Utility
Orally Administered Combinations of Beta-lactam Antibiotics and Avibactam Derivatives for Treating Bacterial Infections
4 Mar 21
Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed.
APP
Utility
Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore
4 Mar 21
Inventors: Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
APP
Utility
ANTI-IL-2 Antibodies and Compositions and Uses Thereof
4 Mar 21
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.
GRANT
Utility
GLP-1 receptor agonists and uses thereof
2 Mar 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
APP
Utility
Therapeutic Antibodies and Their Uses
25 Feb 21
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3).
Transcripts
2020 Q4
Earnings call transcript
2 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
28 Apr 20
2019 Q4
Earnings call transcript
28 Jan 20
2019 Q3
Earnings call transcript
29 Oct 19
2019 Q2
Earnings call transcript
29 Jul 19
2019 Q1
Earnings call transcript
30 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
30 Oct 18
Reddit threads
How to stop chasing the rabbit?
6 Mar 21
I've never seen a stock react so poorly to good news like BB does
6 Mar 21
Made a list of dividend stocks, thoughts?
5 Mar 21
Finding a needle in a dumpster fire
5 Mar 21
Thoughts on Pfizer?
5 Mar 21
What is everyone buying?!? What is your favorite watchlist item? Let's talk value!
5 Mar 21
Preplanned dip before stimulus
5 Mar 21
Market's on sale! What'd you add and whats on your watch list?
4 Mar 21
Dividend beginner
4 Mar 21
Daily Advice Thread - All basic help or advice questions must be posted here.
4 Mar 21